Bone filling scaffold material composition for osteomyelitis and preparation method thereof

Abstract

This application discloses a bone-filling scaffold material composition for osteomyelitis and a preparation method thereof, comprising a first component and a second component; the first component comprising, by weight, 1 to 5 parts of a cyclic monomer and 1 to 10 parts of a double-bond-containing monomer; and the second component comprising, by weight, 0.0011 to 12 parts of a metal ion compound. In the high-ROS environment of excessive inflammation, the metal ions in the bone-filling scaffold material composition provided herein undergo a Fenton reaction with H₂O₂ to generate hydroxyl radicals with higher oxidation potential. The energy generated by the Fenton reaction and the action of the free radicals cause crosslinking and entanglement between polymer chains, thereby improving the mechanical properties of the material and achieving self-reinforcement. The composition also effectively reduces the amount of residual monomer in the material and improves its biocompatibility.

Description

Technical Field

[0001] The present application relates to the field of biomedical materials, and in particular to a bone-filling scaffold material composition for osteomyelitis and a preparation method thereof. Background Art

[0002] Osteomyelitis is a serious bone infection that causes great pain to patients and presents many challenges in its treatment. Currently, treatments for osteomyelitis include surgical debridement and antibiotic therapy, but traditional treatments have many limitations, such as antibiotic resistance and difficulty in completely clearing infected lesions. In particular, because the lesions of chronic osteomyelitis are often surrounded by ischemic tissue, and bacterial colonization forms a biofilm on their surface, antibiotics in the blood have difficulty entering the lesions. Therefore, it is generally difficult to completely cure chronic osteomyelitis with the use of antibiotics alone, and combined surgical treatment is usually required.

[0003] Currently, the most commonly used surgical debridement strategy in clinical practice is the two-stage Max-Scholet technique, also known as the induced membrane technique. This technique involves implanting a specific bone defect reconstruction material, which stimulates the surrounding tissue to form a bioactive membrane structure. The induced membrane is well vascularized, contains a large number of mature mesenchymal stem cells, and secretes various growth factors, creating a local microenvironment conducive to tissue regeneration. The first stage involves debridement and placement of an antibiotic-containing polymethyl methacrylate (PMMA) spacer to sterilize and induce vascular membrane formation. The second stage involves removal of the spacer and bone grafting within the induced membrane. While PMMA implantation stimulates the formation of the induced membrane, providing a favorable environment for secondary bone grafting, its non-degradability prevents effective antibiotic release, resulting in insufficient local antibiotic concentrations. Long-term indwelling can also lead to recurrent infection. Furthermore, it carries certain toxic side effects, lacks osteoconductivity, and requires secondary grafting. This has led many researchers to focus on biodegradable biomaterials in recent years.

[0004] Polymer materials, due to their excellent biocompatibility, degradability, and mechanical properties, have become a research hotspot for bone defect repair. With the advancement of materials science and biomedical engineering, breakthroughs have been made in the application of polymer materials in bone defect repair, providing new solutions for clinical treatment. However, bone repair materials still need to be improved in terms of anti-infection and mechanical properties. Therefore, the development of novel bone repair materials with antibacterial and self-reinforcing properties is of great significance for the treatment of osteomyelitis. Summary of the Invention

[0005] In view of this, the present application provides a bone filling scaffold material that is in situ cured by a cross-linking agent, effectively fills the defect area, and gradually degrades as the bone heals; the second component can undergo a Fenton / Fenton-like reaction with H2O2 in the inflammatory microenvironment to generate hydroxyl radicals (•OH), thereby achieving antibacterial properties, triggering cross-linking of residual monomers in the first component, enhancing the modulus and bonding strength of the bone filling material, and promoting bone healing.

[0006] This application provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component; the first component comprises, by weight, 1 part of a cyclic monomer and 1 to 10 parts of a double-bond-containing monomer; the second component comprises, by weight, 0.0011 to 12 parts of a metal ion compound. The bone filling scaffold material composition provided herein responds to reactive oxygen species (ROS) in the inflammatory environment, releasing hydroxyl radicals that are potently bactericidal, enhancing cross-linking of olefin monomers, reducing residual monomer content, lowering toxicity, and enhancing modulus compatibility between the material and hard bone. It has potential for use as a filling and repair material for osteomyelitis-induced bone defects. The bone filling scaffold material composition for osteomyelitis is simple to prepare, ready for use, and convenient to use. It has an ideal operating time window of 1-3 minutes and strong clinical controllability.

[0007] The present application describes a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component; the first component comprises a cyclic monomer. In some specific implementations, the cyclic monomer includes, but is not limited to, norbornene, a cycloenone acetal compound, or a lipoic acid compound. The present application has no special requirements for the selection of the cyclic monomer, and norbornene is preferred. In some specific implementations, the lipoic acid compound includes one or more of lipoic acid, amidated lipoic acid compounds, aminated lipoic acid, or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, cyanated lipoic acid, or N-hydroxysuccinimide amidated lipoic acid compounds. The mass fraction of the cyclic monomer is 1 to 5 parts, and can be 1 part, 2 parts, 3 parts, 4 parts, or 5 parts. Cyclic monomers include amidated lipoic acid compounds such as aminoethanol and ethylenediamine, lipoic acid modified with amino groups such as ethylenediamine, or lipoic acid compounds with other groups introduced via amidation reaction with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The cycloenone acetal compounds include, but are not limited to, 2-methylene-1,3-dioxepane and / or 5,6-benzo-2-methylene-1,3-dioxepane. This application does not have any specific requirements for the selection of cycloenone acetal compounds.

[0008] The first component described in this application includes a double-bond-containing monomer. In some specific implementations, the double-bond-containing monomer includes, but is not limited to, one or more of acrylic acid, methacrylic acid, acrylamide, methacrylamide, hydroxyethyl acrylate, 2-hydroxymethacrylate, methacrylated chitosan, hydroxyethyl methacrylate, or acrylated gelatin. This application has no specific requirements for the selection of the double-bond-containing monomer. The weight fraction of the double-bond-containing monomer is 1 to 10 parts, and can be 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, or 10 parts. The molar ratio of the cyclic monomer to the double-bond-containing monomer is 1:(0.1-10), preferably 1:0.5.

[0009] The first component described in this application includes an initiator. In some specific implementations, the initiator includes but is not limited to dibenzoyl peroxide and / or N,N-dimethyl-p-toluidine. This application has no special requirements for the selection of the initiator. The weight fraction of the initiator is 0.001 to 0.1 parts, and can be 0.001 parts, 0.005 parts, 0.01 parts, 0.02 parts, 0.03 parts, 0.04 parts, 0.05 parts, 0.08 parts, 0.09 parts, 0.095 parts, or 0.1 parts.

[0010] The first component described herein includes a crosslinking agent. In some specific implementations, the crosslinking agent includes, but is not limited to, one or more of ethylene glycol dimethacrylate, maleic anhydride, or trimethylolpropane triacrylate. The present application has no particular requirements for the selection of the crosslinking agent. The crosslinking agent is present in an amount of 0.001 to 0.1 parts by weight, and may be 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.08, 0.09, 0.095, or 0.1 parts by weight.

[0011] The second component described herein includes a metal ion compound. In some specific implementations, the metal ion compound includes, but is not limited to, one or more of cobalt acetylacetonate, copper acetylacetonate, cobalt sulfide, copper sulfide, calcium sulfide, ferric sulfide, cobalt chloride, copper chloride, calcium chloride, or ferric chloride. The present application has no specific requirements for the selection of the metal ion compound. The weight fraction of the metal ion compound is 0.0011 to 12 parts, and may be 0.0011, 0.01, 0.02, 0.05, 0.1, 0.5, 1, 2, 5, 8, 10, 11, or 12 parts. In some specific implementations, the mass ratio of the first component to the second component is 1:(0.001-1), preferably 1:0.01. In some specific implementations, the volume fraction of the metal ion compound in the osteomyelitis bone filling scaffold material composition is 3% to 8%, preferably 5%.

[0012] The second component described in the present application includes an organic compound. In some specific implementations, the organic compound includes but is not limited to one or more of phenol, glucose, polyvinyl alcohol, chitosan, cellulose, tannic acid, citric acid, polyacrylic acid, ethylenediaminetetraacetic acid, vitamin C, oxalic acid, thioglycolic acid, ethylenediamine or sodium alginate. The present application has no special requirements for the selection of organic compounds. The mass fraction of the organic compound is 0.01 to 10 parts, which can be 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 parts. The second component includes functional components containing mono- / polyhydroxyl groups and carboxyl groups that can coordinate with metal ions to form nanostructures, preferably phenols and other components that can coordinate with metal ions to form metal organic frameworks, polyhydroxy compounds such as glucose, polyvinyl alcohol, chitosan, cellulose, and tannic acid that can coordinate with metal ions to form nanostructures, and components such as citric acid, polyacrylic acid, ethylenediaminetetraacetic acid, vitamin C, and sodium alginate that can form nanostructures with metal ions. The second component also includes 0.1 to 20 parts by weight of a solvent; the solvent includes but is not limited to dimethyl sulfoxide and / or ethanol. The present application has no special requirements for the choice of solvent. The solvent is present in an amount of 0.1 to 20 parts by weight, and can be 0.1, 0.5, 1, 2, 3, 5, 8, 10, 12, 15, 18, or 20 parts.

[0013] The osteomyelitis bone filling scaffold material composition described in the present application utilizes hydrogen peroxide in the osteomyelitis microenvironment to produce hydroxyl radicals through the Fenton reaction, thereby achieving effective killing of infected bacteria and reducing the risk of recurrence of infection. Self-reinforcement is achieved during the polymerization process, improving the mechanical strength of the material, better meeting the mechanical requirements of the bone repair process, and providing stable support for the fracture site. The addition of low-concentration metal ions or bioactive substances promotes the repair and regeneration of bone tissue, contributes to improving the treatment success rate, and reduces the occurrence of complications such as nonunion. The material gradually degrades in the body to avoid long-term retention in the body causing adverse reactions, and the degradation products are non-toxic and harmless and can be metabolized and discharged by the human body.

[0014] The present application also provides a method for preparing a bone-filled scaffold material composition for osteomyelitis, comprising:

[0015] The cyclic monomer and the double bond-containing monomer are mixed to obtain a first component, and the metal ion compound is used as a second component;

[0016] The first component and the second component are mixed to obtain a bone filling scaffold material composition for osteomyelitis.

[0017] In some specific implementations, the time for mixing the first component and the second component is 1s to 100s, preferably 3s to 60s, and more preferably 5s to 20s. In some specific implementations, the mixing of the first component and the second component includes ultrasound, and the ultrasound time is 5-60s.

[0018] The bone filling scaffold material composition for osteomyelitis described in the present application undergoes a polymerization reaction with hydrogen peroxide in the osteomyelitis environment to form a bone filling material;

[0019] In some specific implementations, the polymerization reaction temperature is 20°C to 50°C, preferably 30°C to 40°C; the polymerization reaction is carried out in the presence of a crosslinking agent and an initiator, and the polymerization reaction time is 1 second to 100 seconds, preferably 3 seconds to 60 seconds, and more preferably 5 seconds to 20 seconds. In some specific implementations, hydrogen peroxide can be provided directly from the osteomyelitis environment or generated by adding calcium peroxide, glucose oxidase, or peroxidase to react with the osteomyelitis environment.

[0020] When applied to the fractured bone or filling a bone defect, the first and second components are mixed and then quickly applied or filled. A free radical ring-opening polymerization reaction rapidly occurs, achieving rapid bonding and closure of the broken bone or perfect filling and curing of the bone defect. The osteomyelitis bone filling scaffold material composition has a curing time of 1 to 300 seconds, preferably 30 to 120 seconds.

[0021] In the bone filling scaffold material composition for osteomyelitis provided in the present application, in a high ROS environment of excessive inflammation, metal ions will undergo a Fenton reaction with H2O2 to generate hydroxyl free radicals with higher oxidation potential. Due to the energy generated by the Fenton reaction and the action of free radicals, cross-linking and entanglement occur between polymer chains, thereby improving the mechanical properties of the bone filling scaffold material composition for osteomyelitis and achieving self-reinforcement; and effectively reducing the amount of residual monomers in the material, thereby improving the biocompatibility of the material. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a schematic diagram of the effectiveness of the bone filling scaffold material composition for osteomyelitis provided in Example 1 of the present application. DETAILED DESCRIPTION

[0023] It should be understood that the expression "one or more of" includes individually each of the items recited after the expression and various combinations of two or more of the recited items, unless otherwise apparent from the context and usage. The expression "and / or" in conjunction with three or more recited items should be understood to have the same meaning, unless otherwise apparent from the context.

[0024] The terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, e.g., not excluding other unrecited elements or steps, unless otherwise specifically stated or understood from the context.

[0025] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the application remains operable. Additionally, two or more steps or actions may be performed simultaneously.

[0026] The use of any and all examples or exemplary language such as "for example" or "including" herein is intended only to better illustrate the present application and does not limit the scope of the present application. No language in this specification should be construed as indicating any non-claimed element is essential to the practice of the present application.

[0027] In addition, the numerical ranges and parameters used to define this application are approximate values. The relevant numerical values ​​in the specific examples have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual testing methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, amounts, values, and percentages used in this disclosure are modified by the word "about." As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range.

[0028] The present application provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component; the first component comprises 1 to 5 parts by mass of a cyclic monomer and 0.1 to 10 parts by mass of a double bond-containing monomer; the second component comprises 0.0011 to 12 parts by mass of a metal ion compound.

[0029] The schematic diagram of the effectiveness of the bone filling scaffold material composition for osteomyelitis is as follows Figure 1 As shown, in the bone filling scaffold material composition for osteomyelitis provided by the present application, in a high ROS environment of excessive inflammation, metal ions will react with H2O2 to produce hydroxyl radicals with higher oxidation potential. Due to the energy generated by the Fenton reaction and the action of the free radicals, cross-linking and entanglement occur between the polymer chains, thereby improving the mechanical properties of the material and achieving self-reinforcement; and effectively reducing the residual monomer amount in the bone filling scaffold material composition for osteomyelitis, thereby improving the biocompatibility of the material.

[0030] The present application is further described below with reference to the following examples. The scope of protection of the present application is not limited by the following examples. Example 1

[0031] This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of a cycloenone acetal cyclic monomer (2-methylene-1,3-dioxepane, MDO), 1 part of a double bond-containing monomer (hydroxyethyl methacrylate HEMA), 0.02 parts of an initiator (0.01 parts of dibenzoyl peroxide and 0.01 parts of N,N-dimethyl-p-toluidine), and 0.02 parts of a cross-linking agent (ethylene glycol dimethacrylate); and the second component comprises 0.2 parts of a metal ion compound (cobalt acetylacetonate).

[0032] The preparation method of the bone filling scaffold material composition for osteomyelitis comprises:

[0033] Mixing a cyclic monomer, a double bond-containing monomer, a crosslinking agent, and an initiator to obtain a first component;

[0034] Cobalt acetylacetonate is added to the first component, and the mixture is evenly mixed by blowing or ultrasonication to prepare a bone filling scaffold material composition for osteomyelitis containing metal ions with a volume fraction of 5%. Example 2

[0035] This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of a cycloenone acetal cyclic monomer (MDO), 1 part of a double bond-containing monomer (HEMA), 0.02 parts of an initiator (0.01 parts of dibenzoyl peroxide and 0.01 parts of N,N-dimethyl-p-toluidine), and 0.02 parts of a cross-linking agent (ethylene glycol dimethacrylate); and the second component comprises 0.2 parts of a metal ion compound (CoCl2).

[0036] The preparation method of the bone filling scaffold material composition for osteomyelitis is the same as that in Example 1. Example 3

[0037] This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of a cycloenone acetal cyclic monomer (MDO), 1 part of a double bond-containing monomer (HEMA), 0.02 parts of an initiator (0.01 parts of dibenzoyl peroxide and 0.01 parts of N,N-dimethyl-p-toluidine), and 0.02 parts of a cross-linking agent (ethylene glycol dimethacrylate); the second component comprises 0.2 parts of a metal ion compound (CoCl2) and 0.1 parts of a carboxyl-containing compound (alginate, carboxymethyl chitosan).

[0038] The preparation method of the bone filling scaffold material composition for osteomyelitis is the same as that in Example 1. Example 4

[0039] This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of N-hydroxysuccinimide amidated lipoic acid, 1 part of a double bond-containing monomer (HEMA, methacryloylated chitosan), 0.01 part of an initiator (0.005 parts of dibenzoyl peroxide and 0.005 parts of N,N-dimethyl-p-toluidine), and 0.01 part of a cross-linking agent (ethylene glycol dimethacrylate); and the second component comprises 0.2 parts of a metal ion compound (cobalt acetylacetonate, copper acetylacetonate).

[0040] The preparation method of the bone filling scaffold material composition for osteomyelitis is the same as that in Example 1. Example 5

[0041] This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of N-hydroxysuccinimide amidated lipoic acid, 1 part of a double bond-containing monomer (HEMA, methacryloylated chitosan), 0.01 part of an initiator (0.005 parts of dibenzoyl peroxide and 0.005 parts of N,N-dimethyl-p-toluidine), and 0.01 part of a cross-linking agent (ethylene glycol dimethacrylate); the second component comprises 0.2 parts of a metal ion compound (CoCl2, FeCl3).

[0042] The preparation method of the bone filling scaffold material composition for osteomyelitis is the same as that in Example 1. Example 6

[0043] This embodiment provides a bone filling scaffold material composition for osteomyelitis. This embodiment provides a bone filling scaffold material composition for osteomyelitis, comprising a first component and a second component, wherein the first component comprises 1 part of N-hydroxysuccinimide amidated lipoic acid, 1 part of a double bond-containing monomer (HEMA, methacryloylated chitosan), 0.01 part of an initiator (0.005 part of dibenzoyl peroxide and 0.005 part of N,N-dimethyl-p-toluidine) and 0.01 part of a cross-linking agent (ethylene glycol dimethacrylate); the second component comprises 0.2 part of a metal ion compound (CoCl2).

[0044] The preparation method of the bone filling scaffold material composition for osteomyelitis is the same as that in Example 1. Comparative Example 1

[0045] This embodiment provides a bone filling scaffold material composition for osteomyelitis, which differs from Example 1 in that no metal ionizer is added. Comparative Example 2

[0046] This embodiment provides a bone filling scaffold material composition for osteomyelitis, which differs from Example 1 in that the metal ion compound is replaced with the commercially available antibiotic vancomycin.

[0047] The performance test of the bone filling scaffold material composition for osteomyelitis provided in Examples 1 to 6 and Comparative Examples 1 to 2 was performed, and the test method was as follows:

[0048] Antibacterial performance test: Staphylococcus aureus and Escherichia coli were cultured to the logarithmic phase, and the bacteria were washed with sterile PBS solution. Then, a sample of the bone filling scaffold material composition for osteomyelitis was added to 2 mL of a bacterial suspension with a predetermined concentration. Different amounts of H2O2 solution were added. The culture solution of the bone filling scaffold material composition for osteomyelitis and common pathogens of osteomyelitis, such as Staphylococcus aureus and Escherichia coli, was diluted using the plate colony count method. The solution was then spread on LB solid culture medium and incubated in a 37°C incubator for 16 hours. The number of colonies was then observed and counted to evaluate the antibacterial performance of the material. The test results are shown in Table 1.

[0049] Self-reinforcement performance test: A universal testing machine was used to test the mechanical properties and bonding strength of the osteomyelitis bone filling scaffold material composition to bone tissue. The test process was as follows: 100uL of the preliquid of the osteomyelitis bone filling scaffold material composition after the different components were evenly mixed was evenly applied to the surface of the bone block (25mm×25mm). After curing at room temperature for 3 minutes, the bone block was immersed in a 10mM H2O2 solution for 30 minutes. Finally, a combined tensile test was performed using a universal testing machine; or the bulk properties of the preformed bone filling material were measured through compression tests. The test results are shown in Table 2.

[0050]

[0051]

[0052] The results in Table 1 show that compared to the control group without the addition of metal ions and antibiotics, the number of colonies around the osteomyelitis bone filling scaffold material composition provided in Examples 1-6 of the present application was significantly reduced, with a sterilization rate of over 83% against Escherichia coli and over 85% against Staphylococcus aureus, demonstrating its good antibacterial effect. The results in Table 2 show that compared to Comparative Examples 1-2, the osteomyelitis bone filling scaffold material composition containing metal ions in Examples 1-6 has better mechanical properties; the presence of H2O2 gradually enhances the mechanical properties of the osteomyelitis bone filling scaffold material composition in the present application, achieving mechanical self-reinforcement in the highly inflammatory environment of osteomyelitis to better match the mechanical requirements of the bone at the filling site.

[0053] The test results show that the bone filling scaffold material composition for osteomyelitis provided in this application has a lap shear tensile strength of 0.3-10 MPa for bone tissue and a superimposed bonding strength of 0.5-20 MPa for bone tissue, showing good bone tissue bonding performance; the compression modulus is 10-100 MPa, closely matching the modulus of the adhered bone tissue. In the inflammatory microenvironment present with ROS, the material consumes H₂O₂, releasing bactericidal •OH with a bactericidal rate of ≥90% against Escherichia coli and ≥92% against Staphylococcus aureus, demonstrating excellent antibacterial properties. The released •OH also promotes further cross-linking of residual double-bond monomers, cross-linkers, and cyclic monomers in the material system, thereby reducing the residual monomer content to ≤5% and cytotoxicity to ≤15%. In a mouse osteomyelitis model, residual bacteria remained ≤10% after 7 days of implantation and ≤5% after 14 days. Its biodegradability ensures that the material does not hinder bone repair, with degradation levels of ≥20% after 30 days and ≥40% after 60 days, demonstrating excellent degradation properties and a good match for bone tissue growth. Its degradation rate can be controlled by adjusting the type and ratio of ring-openable monomers and the concentration of metal ions, matching the bone repair process. After bone regeneration is complete, it gradually degrades and disappears, avoiding the need for secondary surgical removal.

[0054] The above is only a preferred specific implementation method of the present application, but the scope of protection of the present application is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes based on the technical solution and application concept of the present application within the technical scope disclosed in the present application, and they should be covered by the scope of protection of the present application.

Claims

1. A bone filling scaffold material composition for osteomyelitis, characterized in that: The invention comprises a first component and a second component; the first component comprises, by weight, 1 to 5 parts of a cyclic monomer, 1 to 10 parts of a double bond-containing monomer, 0.001 to 0.1 parts of an initiator, and 0.001 to 0.1 parts of a cross-linking agent; the second component comprises, by weight, 0.0011 to 12 parts of a metal ion compound and 0.1 to 20 parts of a solvent; The metal ion compound includes one or more of cobalt acetylacetonate, copper acetylacetonate, cobalt sulfide, copper sulfide, iron sulfide, cobalt chloride, copper chloride or iron chloride; The cyclic monomer includes one or more of 2-methylene-1,3-dioxolane, 5,6-benzo-2-methylene-1,3-dioxepane, lipoic acid, amidated lipoic acid compounds, aminated lipoic acid, cyanated lipoic acid, or N-hydroxysuccinimide amidated lipoic acid compounds; The double bond-containing monomer includes one or more of acrylic acid, methacrylic acid, acrylamide, methacrylamide, hydroxyethyl acrylate, 2-hydroxymethacrylate, methacrylated chitosan, hydroxyethyl methacrylate or acrylated gelatin; The initiator includes dibenzoyl peroxide and / or N,N-dimethyl-p-toluidine; the crosslinking agent includes one or more of ethylene glycol dimethacrylate, maleic anhydride or trimethylolpropane triacrylate; The solvent includes ethanol.

2. The bone filling scaffold material composition for osteomyelitis according to claim 1, characterized in that: The second component further comprises 0.01 to 10 parts by mass of an organic compound; The organic compound includes one or more of phenol, glucose, polyvinyl alcohol, chitosan, cellulose, tannic acid, citric acid, polyacrylic acid, ethylenediaminetetraacetic acid, vitamin C, oxalic acid, thioglycolic acid, alginic acid, carboxymethyl chitosan, ethylenediamine or sodium alginate.

3. The bone filling scaffold material composition for osteomyelitis according to claim 1, characterized in that: The mass ratio of the first component to the second component is 1:(0.001-1).

4. A method for preparing the bone filling scaffold material composition for osteomyelitis according to any one of claims 1 to 3, characterized in that: include: Mixing a cyclic monomer, a double bond-containing monomer, an initiator, and a cross-linking agent to obtain a first component, and mixing a metal ion compound with a solvent to obtain a second component; The first component and the second component are mixed to obtain a bone filling scaffold material composition for osteomyelitis.

5. The preparation method according to claim 4, characterized in that The time for mixing the first component and the second component is 1s to 100s.

Images